Read More Pharma Industry News Legend Biotech (NASDAQ: LEGN) CARVYKTI scaling meets LB2102 solid tumor signal Legend Biotech (NASDAQ: LEGN) printed 62% CARVYKTI growth and a solid tumor CAR-T signal. The 2026 profitability target is the next real test. bySrinathJune 23, 2026